June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Aqueous Levels of VEGF Decrease After Serial Intravitreal Injections of Anti-VEGF Agents in Patients with Diabetic Retinopathy
Author Affiliations & Notes
  • Bharani Krishna Mynampati
    Ophthalmology, University of Florida Health Science Center Jacksonville, Jacksonville, Florida, United States
  • Ghulam Shabbir Hamdani
    Ophthalmology, University of Florida Health Science Center Jacksonville, Jacksonville, Florida, United States
  • kerry anne bell
    Ophthalmology, University of Florida Health Science Center Jacksonville, Jacksonville, Florida, United States
  • Darrell WuDunn
    Ophthalmology, University of Florida Health Science Center Jacksonville, Jacksonville, Florida, United States
  • Sandeep Grover
    Ophthalmology, University of Florida Health Science Center Jacksonville, Jacksonville, Florida, United States
  • Footnotes
    Commercial Relationships   Bharani Krishna Mynampati None; Ghulam Shabbir Hamdani None; kerry anne bell None; Darrell WuDunn None; Sandeep Grover None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 314 – F0117. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bharani Krishna Mynampati, Ghulam Shabbir Hamdani, kerry anne bell, Darrell WuDunn, Sandeep Grover; Aqueous Levels of VEGF Decrease After Serial Intravitreal Injections of Anti-VEGF Agents in Patients with Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2022;63(7):314 – F0117.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To measure the levels of VEGF in aqueous before and after treatment in patients with diabetic retinopathy treated with anti-VEGF agents. This was compared to VEGF levels in control eyes

Methods : The study was approved by the local University IRB. Aqueous samples were collected at the time of paracentesis following each intravitreal injection of an anti-VEGF agent given serially every 4 – 6 weeks in patients with proliferative diabetic retinopathy (PDR) or diabetic macular edema (DME). The control eyes consisted of aqueous collected from patients without diabetes or any retinal disease, undergoing cataract surgery. These samples were immediately stored in -800 C freezer. At the time of analysis, aqueous samples were thawed at room temperature and VEGF (pg/ml) levels were measured using human premixed multi-analyte kit and magnetic bead assay on Luminex MAGPIX analyzer (Austin, TX, USA).

Results : In 203 samples from 59 eyes, the average VEGF level from the first sample measured in
each eye was 198.3 pg/ml. This decreased significantly to an average level of 26.5 pg/ml in the
last sample measured from each eye after 2-9 injections of an anti-VEGF agent (average, 3.4 injections). In 64 control eyes, the average level of VEGF was 34.06 pg/ml. The change in VEGF levels correlated with the retinal thickness on OCT

Conclusions : Aqueous levels of VEGF can be easily measured at every injection in patients with diabetic retinopathy. Aqueous levels of VEGF were significantly reduced after treatment with anti-VEGF agents. With the ease of obtaining the aqueous sample and measuring the VEGF levels, this maybe a useful parameter in the future, in addition to visual acuity and retinal thickness, to possibly personalize the treatment of patients with diabetic retinopathy.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×